Guía OncoSur de Cáncer de mama 32 > BIBLIOGRAFÍA 1. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumors of the breast. 4th edition. Lyon: IARC; 2012. 2. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with wholebreast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;10;32(14):1507-15. 3. College of American Pathologist. Cancer protocol templates: breast biomarker reporting v1.2.0.1. Available from: http://www.cap.org 4. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-46. 5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA. Molecular portraits of human breast tumours. Nature. 2000;17;406(6797):747-52. Subtipo molecular Inmunohistoquímica Luminal A 40 % RE+ y/o RP+ HER2/neuKi-67 < 20 % Luminal B 20 % RE+ y/o RP+ o RP- (más frecuente) HER2/neu+ en el 25 % y negativo en el 75 % Ki-67 > 20 % Rico enHER2 10-15 % RE-, RPHER2/neu+ Triple negativo 15-20 % RE-, RPHER2/neu85 % fenotipobasal-like (CK5/6, CK14, EGFR) – Tabla VII – Subrogado inmunohistoquímico de la clasificación molecular del cáncer de mama
RkJQdWJsaXNoZXIy MTQzMjMwMg==